Nektar Therapeutics' Long-Term Phase 2 Alopecia Data Supports Phase 3 Advancement for Rezpegaldesleukin

on

Nektar released 52-week data from the blinded extension of the Phase 2b REZOLVE-AA trial showing deepening hair regrowth in alopecia areata patients treated with rezpegaldesleukin.12

In the extension, 29% of low-dose and 31% of high-dose recipients achieved SALT scores of 20 or below, compared to none in the placebo group.1

The company states these results support advancing rezpegaldesleukin into Phase 3 development.123

Nektar's shares surged nearly 25% following the announcement, reaching over $105.1

Safety profile remained favorable with mild to moderate adverse events, mostly injection site reactions, and no discontinuations due to side effects.1

Sources:

1. https://www.biopharmadive.com/news/nektar-rezpegaldesleukin-alopecia-areata-extension-results/817926/

2. https://www.quiverquant.com/news/Nektar+Therapeutics+rallies+after+releasing+new+52-week+alopecia+areata+data+for+rezpegaldesleukin

3. https://investing.com/news/stock-market-news/nektar-therapeutics-stock-surges-on-alopecia-drug-trial-data-93CH-4623885?ampMode=1